ArticleCancer gene therapy2008
Cancer immunotherapy based on recombinant Salmonella enterica serovar Typhimurium aroA strains secreting prostate-specific antigen and cholera toxin subunit B.
Article in Cancer gene therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 69 citations in OpenAlex.
- Engineering Salmonella as an immune-metabolic modulator of the tumor microenvironment.Trends in biotechnology · 2026Review
- Molecular mechanisms of bacteria-mediated cancer immunotherapy: from intratumoral microbiota to engineered therapeutics.Frontiers in immunology · 2026Review
- Repurposing the bacterial surface display technology for drug delivery.Advanced drug delivery reviews · 2025Review
- Mathematical Modeling ofBioengineering (Basel, Switzerland) · 2025Article
- Salmonella cancer therapy metabolically disrupts tumours at the collateral cost of T cell immunity.EMBO molecular medicine · 2024Article
- Exploiting bacteria for cancer immunotherapy.Nature reviews. Clinical oncology · 2024Review
- Article
- Current advances in microbial-based cancer therapies.Medical oncology (Northwood, London, England) · 2023Review
- Recent advances in bacterial therapeutics based on sense and response.Acta pharmaceutica Sinica. B · 2023Review
- Review
- Review
- Recombinant AttenuatedCancers · 2022Review
- Bacterial-Based Cancer Therapy (BBCT): Recent Advances, Current Challenges, and Future Prospects for Cancer Immunotherapy.Vaccines · 2021Review
- In situ delivery of biobutyrate by probiotic Escherichia coli for cancer therapy.Scientific reports · 2021Article
- Metabolic engineering of probiotic Escherichia coli for cytolytic therapy of tumors.Scientific reports · 2021Article
- Targeting ProgrammedCancers · 2019Review
- The potential roles of bacteria to improve radiation treatment outcome.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018Review
- Cancer Immunotherapy: Priming the Host Immune Response with Live AttenuatedJournal of immunology research · 2018Review
- Article
- Strains, Mechanism, and Perspective: Salmonella-Based Cancer Therapy.International journal of microbiology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is the most common malignant tumor in men and is normally associated with increased serum levels of prostate-specific antigen (PSA). Therefore, PSA is one potential target for a prostate cancer vaccine. In this study we analyzed the functionality of new bacterial PSA vaccines, expressed and secreted via the hemolysin (HlyA) secretion system of Escherichia coli, the prototype of Type I secretion systems (T1SS) using an attenuated Salmonella enterica serovar Typhimurium aroA strain as carrier. The data demonstrate that a bacterial live vaccine encompassing T1SS in combination with cholera toxin subunit B can be successfully used for delivery of PSA to induce cytotoxic CD8+ T-cell responses resulting in an efficient prevention of tumor growth in mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.